Positive SARAH result will give long needed confidence to SRX. It will build excitement leading into the FOXFIRE data at ASCO.
If SARAH phase 3 data shows OS benefit in HCC and we already know liver PFS is prolonged in mCRC, then just maybe OS will also be extended in mCRC. Sure they are different clinical scenarios, but I expect a strong lead up into ASCO if SARAH is positive. Get in under $20 now, coz you won't be able to in a couple of months time.
Ann: SARAH Awarded Oral Abstract at Upcoming EASL/ILC Meeting, page-29
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $65.79M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.3¢ | $395.4K | 2.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 2728183 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 84474 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |